2-Oxazolidinone, 5-[3,5-bis(trifluoromethyl)phenyl]-3-[[4-fluoro-2-methoxy-5-(1-methylethyl)-4-(trifluoromethyl)[1,1-biphenyl]-2-yl]methyl]-4-methyl-, (4S,5R)- (BioDeep_00000842571)
代谢物信息卡片
2-Oxazolidinone, 5-[3,5-bis(trifluoromethyl)phenyl]-3-[[4-fluoro-2-methoxy-5-(1-methylethyl)-4-(trifluoromethyl)[1,1-biphenyl]-2-yl]methyl]-4-methyl-, (4S,5R)-
化学式: C30H25F10NO3 (637.1674659999999)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1C(OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
InChI: InChI=1S/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3
描述信息
D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents
D000890 - Anti-Infective Agents > D023303 - Oxazolidinones
D009676 - Noxae > D000963 - Antimetabolites
同义名列表
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Mathieu R Brodeur, David Rhainds, Daniel Charpentier, Marie Boulé, Téodora Mihalache-Avram, Mélanie Mecteau, Geneviève Brand, Valérie Pedneault-Gagnon, Annik Fortier, Eric J Niesor, Eric Rhéaume, Cyrille Maugeais, Jean-Claude Tardif. Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans.
Journal of lipid research.
2023 01; 64(1):100316. doi:
10.1016/j.jlr.2022.100316. [PMID: 36410424] - E Sammons, J C Hopewell, F Chen, W Stevens, K Wallendszus, E Valdes-Marquez, R Dayanandan, C Knott, K Murphy, E Wincott, A Baxter, R Goodenough, M Lay, M Hill, S Macdonnell, G Fabbri, D Lucci, M Fajardo-Moser, S Brenner, D Hao, H Zhang, J Liu, B Wuhan, S Mosegaard, W Herrington, C Wanner, C Angermann, G Ertl, A Maggioni, P Barter, B Mihaylova, Y Mitchel, R Blaustein, S Goto, J Tobert, P DeLucca, Y Chen, Z Chen, A Gray, R Haynes, J Armitage, C Baigent, S Wiviott, C Cannon, E Braunwald, R Collins, L Bowman, M Landray. Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.
European heart journal.
2022 04; 43(14):1416-1424. doi:
10.1093/eurheartj/ehab863. [PMID: 34910136] - Amand F Schmidt, Nicholas B Hunt, Maria Gordillo-Marañón, Pimphen Charoen, Fotios Drenos, Mika Kivimaki, Deborah A Lawlor, Claudia Giambartolomei, Olia Papacosta, Nishi Chaturvedi, Joshua C Bis, Christopher J O'Donnell, Goya Wannamethee, Andrew Wong, Jackie F Price, Alun D Hughes, Tom R Gaunt, Nora Franceschini, Dennis O Mook-Kanamori, Magdalena Zwierzyna, Reecha Sofat, Aroon D Hingorani, Chris Finan. Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease.
Nature communications.
2021 09; 12(1):5640. doi:
10.1038/s41467-021-25703-3. [PMID: 34561430] - Petr Vachal, Joseph L Duffy, Louis-Charles Campeau, Rupesh P Amin, Kaushik Mitra, Beth Ann Murphy, Pengcheng P Shao, Peter J Sinclair, Feng Ye, Revathi Katipally, Zhijian Lu, Debra Ondeyka, Yi-Heng Chen, Kake Zhao, Wanying Sun, Sriram Tyagarajan, Jianming Bao, Sheng-Ping Wang, Josee Cote, Concetta Lipardi, Daniel Metzger, Dennis Leung, Georgy Hartmann, Gordon K Wollenberg, Jian Liu, Lushi Tan, Yingju Xu, Qinghao Chen, Guiquan Liu, Robert O Blaustein, Douglas G Johns. Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties.
Journal of medicinal chemistry.
2021 09; 64(18):13215-13258. doi:
10.1021/acs.jmedchem.1c00959. [PMID: 34375108] - Hanjing Chen, Weili Chen, Hui Li, Hongrong Xu, Fei Yuan, Lei Sheng, Chao Liu, Pingping Lin, Mengjie Yang, Xuening Li, Yang Liu, Brittany Marie Walker, Ferdous Gheyas, Marian Iwamoto, S Aubrey Stoch, Rajesh Krishna. Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects.
Advances in therapy.
2021 07; 38(7):3973-3985. doi:
10.1007/s12325-021-01794-8. [PMID: 34101144] - Mark Trinder, Yanan Wang, Christian M Madsen, Tatjana Ponomarev, Lubos Bohunek, Brendan A Daisely, HyeJin Julia Kong, Lisanne L Blauw, Børge G Nordestgaard, Anne Tybjærg-Hansen, Mark M Wurfel, James A Russell, Keith R Walley, Patrick C N Rensen, John H Boyd, Liam R Brunham. Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis.
Circulation.
2021 03; 143(9):921-934. doi:
10.1161/circulationaha.120.048568. [PMID: 33228395] - Mark P Metzinger, Suzanne Saldanha, Jaskeerat Gulati, Kershaw V Patel, Ayea El-Ghazali, Sneha Deodhar, Parag H Joshi, Colby Ayers, Anand Rohatgi. Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial.
Journal of the American Heart Association.
2020 12; 9(24):e018136. doi:
10.1161/jaha.120.018136. [PMID: 33263263] - Douglas G Johns, Sheng-Ping Wang, Raymond Rosa, James Hubert, Suoyu Xu, Ying Chen, Thomas Bateman, Robert O Blaustein. Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case.
Pharmacology research & perspectives.
2019 12; 7(6):e00543. doi:
10.1002/prp2.543. [PMID: 31832204] - Ben J Wu, Yue Li, Kwok-Leung Ong, Yidan Sun, Douglas Johns, Philip J Barter, Kerry-Anne Rye. The Cholesteryl Ester Transfer Protein Inhibitor, des-Fluoro-Anacetrapib, Prevents Vein Bypass-induced Neointimal Hyperplasia in New Zealand White Rabbits.
Scientific reports.
2019 11; 9(1):16183. doi:
10.1038/s41598-019-52510-0. [PMID: 31700015] - Sneha M Dixit, Mohd Ahsan, Sanjib Senapati. Steering the Lipid Transfer To Unravel the Mechanism of Cholesteryl Ester Transfer Protein Inhibition.
Biochemistry.
2019 09; 58(36):3789-3801. doi:
10.1021/acs.biochem.9b00301. [PMID: 31418269] - Douglas G Johns, Lauretta LeVoci, Mihajlo Krsmanovic, Min Lu, Georgy Hartmann, Suoyu Xu, Sheng-Ping Wang, Ying Chen, Thomas Bateman, Robert O Blaustein. Characterization of Anacetrapib Distribution into the Lipid Droplet of Adipose Tissue in Mice and Human Cultured Adipocytes.
Drug metabolism and disposition: the biological fate of chemicals.
2019 03; 47(3):227-233. doi:
10.1124/dmd.118.084525. [PMID: 30567880] - Rajesh Krishna, Ferdous Gheyas, Christy Corr, Josee Cote, Yang Liu, John Wagner, David E Gutstein. Pharmacokinetics and Pharmacodynamics of Anacetrapib in Black and White Healthy Subjects.
Journal of clinical pharmacology.
2018 12; 58(12):1578-1585. doi:
10.1002/jcph.1287. [PMID: 30029292] - Lin Zhu, Thao Luu, Christopher H Emfinger, Bryan A Parks, Jeanne Shi, Elijah Trefts, Fenghua Zeng, Zsuzsanna Kuklenyik, Raymond C Harris, David H Wasserman, Sergio Fazio, John M Stafford. CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet.
Diabetes.
2018 12; 67(12):2494-2506. doi:
10.2337/db18-0474. [PMID: 30213825] - Philip J Barter, Blake J Cochran, Kerry-Anne Rye. CETP inhibition, statins and diabetes.
Atherosclerosis.
2018 11; 278(?):143-146. doi:
10.1016/j.atherosclerosis.2018.09.033. [PMID: 30278356] - Zhiwei Yang, Yang Cao, Dongxiao Hao, Xiaohui Yuan, Lei Zhang, Shengli Zhang. Binding profiles of cholesterol ester transfer protein with current inhibitors: a look at mechanism and drawback.
Journal of biomolecular structure & dynamics.
2018 Aug; 36(10):2567-2580. doi:
10.1080/07391102.2017.1363661. [PMID: 28777919] - Yusuke Masuda, Shinji Yamaguchi, Chikako Suzuki, Takahide Aburatani, Yuki Nagano, Ryuki Miyauchi, Eiko Suzuki, Naotoshi Yamamura, Kentaro Nagatomo, Hidetoshi Ishihara, Kazuaki Okuno, Futoshi Nara, Gabriele Matschiner, Ryuji Hashimoto, Tohru Takahashi, Tomohiro Nishizawa. Generation and Characterization of a Novel Small Biologic Alternative to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibodies, DS-9001a, Albumin Binding Domain-Fused Anticalin Protein.
The Journal of pharmacology and experimental therapeutics.
2018 05; 365(2):368-378. doi:
10.1124/jpet.117.246652. [PMID: 29463608] - Sheila A Doggrell. Cardiovascular outcomes trial with anacetrapib in subjects with high cardiovascular risk - are major benefits REVEALed?.
Expert opinion on pharmacotherapy.
2018 Apr; 19(6):611-615. doi:
10.1080/14656566.2018.1448061. [PMID: 29498299] - Rajesh Krishna, Ferdous Gheyas, Yang Liu, Josee Cote, Omar Laterza, Jon L Ruckle, John A Wagner, Andrew E Denker. Pharmacokinetics and Pharmacodynamics of Anacetrapib Following Single Doses in Healthy, Young Japanese and White Male Subjects.
Journal of clinical pharmacology.
2018 02; 58(2):254-262. doi:
10.1002/jcph.1004. [PMID: 28884824] - Alan R Tall, Daniel J Rader. Trials and Tribulations of CETP Inhibitors.
Circulation research.
2018 01; 122(1):106-112. doi:
10.1161/circresaha.117.311978. [PMID: 29018035] - Luis Masana. Results of the REVEAL study. Why Should we not welcome a new lipid lowering agent?.
Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.
2017 Nov; 29(6):278-279. doi:
10.1016/j.arteri.2017.10.002. [PMID: 29173491] - R Krishna, F Gheyas, Y Liu, D R Hagen, B Walker, A Chawla, J Cote, R O Blaustein, D E Gutstein. Chronic Administration of Anacetrapib Is Associated With Accumulation in Adipose and Slow Elimination.
Clinical pharmacology and therapeutics.
2017 Nov; 102(5):832-840. doi:
10.1002/cpt.700. [PMID: 28380664] - Tiffany Thomas, Haihong Zhou, Wahida Karmally, Rajasekhar Ramakrishnan, Stephen Holleran, Yang Liu, Patricia Jumes, John A Wagner, Brian Hubbard, Stephen F Previs, Thomas Roddy, Amy O Johnson-Levonas, David E Gutstein, Santica M Marcovina, Daniel J Rader, Henry N Ginsberg, John S Millar, Gissette Reyes-Soffer. CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects.
Arteriosclerosis, thrombosis, and vascular biology.
2017 09; 37(9):1770-1775. doi:
10.1161/atvbaha.117.309549. [PMID: 28729361] - Christie M Ballantyne, Sukrut Shah, Aditi Sapre, Tanya B Ashraf, Sandra C Tobias, Tayfun Sahin, Ping Ye, Yugang Dong, Wayne Huey-Heng Sheu, Duk-Hyun Kang, Paulo Roberto Ferreira Rossi, Yulia Moiseeva, Ignacio Rodriguez Briones, Amy O Johnson-Levonas, Yale B Mitchel. A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
The American journal of cardiology.
2017 Aug; 120(4):569-576. doi:
10.1016/j.amjcard.2017.03.255. [PMID: 28624096] - Mathieu R Brodeur, David Rhainds, Daniel Charpentier, Teodora Mihalache-Avram, Mélanie Mecteau, Geneviève Brand, Evelyne Chaput, Anne Perez, Eric J Niesor, Eric Rhéaume, Cyrille Maugeais, Jean-Claude Tardif. Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys.
Journal of lipid research.
2017 07; 58(7):1282-1291. doi:
10.1194/jlr.m068940. [PMID: 28515138] - Spencer Phillips Hey, Jessica M Franklin, Jerry Avorn, Aaron S Kesselheim. Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors.
Circulation. Cardiovascular quality and outcomes.
2017 Jun; 10(6):. doi:
10.1161/circoutcomes.116.003121. [PMID: 28611186] - Amanda L Brown, J Mark Brown. Anacetrapib-driven triglyceride lowering explained: the fortuitous role of CETP in the intravascular catabolism of triglyceride-rich lipoproteins.
Journal of lipid research.
2017 06; 58(6):1031-1032. doi:
10.1194/jlr.c077131. [PMID: 28432183] - John S Millar, Michael E Lassman, Tiffany Thomas, Rajasekhar Ramakrishnan, Patricia Jumes, Richard L Dunbar, Emil M deGoma, Amanda L Baer, Wahida Karmally, Daniel S Donovan, Hashmi Rafeek, John A Wagner, Stephen Holleran, Joseph Obunike, Yang Liu, Soumia Aoujil, Taylor Standiford, David E Gutstein, Henry N Ginsberg, Daniel J Rader, Gissette Reyes-Soffer. Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E.
Journal of lipid research.
2017 06; 58(6):1214-1220. doi:
10.1194/jlr.m074880. [PMID: 28314859] - Tamio Teramoto, Hiroyuki Daida, Katsunori Ikewaki, Hidenori Arai, Yuko Maeda, Mariko Nakagomi, Masayoshi Shirakawa, Yuichiro Watanabe, Taro Kakikawa, Hirotaka Numaguchi, Amy O Johnson-Levonas, Robert O Blaustein. Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia.
Atherosclerosis.
2017 06; 261(?):69-77. doi:
10.1016/j.atherosclerosis.2017.03.009. [PMID: 28478132] - L Bowman, F Chen, E Sammons, J C Hopewell, K Wallendszus, W Stevens, E Valdes- Marquez, S Wiviott, C P Cannon, E Braunwald, R Collins, M J Landray. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics.
American heart journal.
2017 05; 187(?):182-190. doi:
10.1016/j.ahj.2017.02.021. [PMID: 28454801] - Claudio Borghi, Arrigo F G Cicero. Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia.
Expert opinion on drug metabolism & toxicology.
2017 Feb; 13(2):205-209. doi:
10.1080/17425255.2017.1262347. [PMID: 27852117] - Sang-Bum Kim, Ki Taek Kim, Jeongmin Joo, Kyung-Ah Seo, Hayoung Hwang, Soong-Hyun Kim, Minsoo Song, Sungwoo Lee, Alexander Jahn, Hyun-Jong Cho, Dae-Duk Kim, In-Soo Yoon. Assessment of pharmacokinetics, bioavailability and protein binding of anacetrapib in rats by a simple high-performance liquid chromatography-tandem mass spectrometry method.
Biomedical chromatography : BMC.
2017 Feb; 31(2):. doi:
10.1002/bmc.3791. [PMID: 27432781] - Christie M Ballantyne, Sukrut Shah, Uma Kher, John A Hunter, Geraldine G Gill, Michael D Cressman, Tanya B Ashraf, Amy O Johnson-Levonas, Yale B Mitchel. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
The American journal of cardiology.
2017 Feb; 119(3):388-396. doi:
10.1016/j.amjcard.2016.10.032. [PMID: 27956003] - Ziyun Wang, Manabu Niimi, Qianzhi Ding, Zhenming Liu, Ling Wang, Jifeng Zhang, Jun Xu, Jianglin Fan. Comparative studies of three cholesteryl ester transfer proteins and their interactions with known inhibitors.
PloS one.
2017; 12(8):e0180772. doi:
10.1371/journal.pone.0180772. [PMID: 28767652] - Venkat R Chirasani, Revathi Sankar, Sanjib Senapati. Mechanism of Inhibition of Cholesteryl Ester Transfer Protein by Small Molecule Inhibitors.
The journal of physical chemistry. B.
2016 08; 120(33):8254-63. doi:
10.1021/acs.jpcb.6b01928. [PMID: 27111423] - T D Filippatos, E Klouras, F Barkas, M Elisaf. Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
Expert review of cardiovascular therapy.
2016 Aug; 14(8):953-62. doi:
10.1080/14779072.2016.1189327. [PMID: 27171534] - Hidenori Arai, Tamio Teramoto, Hiroyuki Daida, Katsunori Ikewaki, Yuko Maeda, Mariko Nakagomi, Masayoshi Shirakawa, Taro Kakikawa, Hirotaka Numaguchi, Amy O Johnson-Levonas, Sanskruti Vaidya, Robert O Blaustein. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia.
Atherosclerosis.
2016 06; 249(?):215-23. doi:
10.1016/j.atherosclerosis.2016.03.017. [PMID: 27131642] - Eder C R Quintão. The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel?.
European journal of clinical investigation.
2016 Jun; 46(6):581-9. doi:
10.1111/eci.12626. [PMID: 26992444] - Gissette Reyes-Soffer, John S Millar, Colleen Ngai, Patricia Jumes, Ellie Coromilas, Bela Asztalos, Amy O Johnson-Levonas, John A Wagner, Daniel S Donovan, Wahida Karmally, Rajasekhar Ramakrishnan, Stephen Holleran, Tiffany Thomas, Richard L Dunbar, Emil M deGoma, Hashmi Rafeek, Amanda L Baer, Yang Liu, Michael E Lassman, David E Gutstein, Daniel J Rader, Henry N Ginsberg. Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
Arteriosclerosis, thrombosis, and vascular biology.
2016 05; 36(5):994-1002. doi:
10.1161/atvbaha.115.306680. [PMID: 26966279] - David G McLaren, Stephen F Previs, Robert D Phair, Steven J Stout, Dan Xie, Ying Chen, Gino M Salituro, Suoyu S Xu, Jose M Castro-Perez, Gregory J Opiteck, Karen O Akinsanya, Michele A Cleary, Hayes M Dansky, Douglas G Johns, Thomas P Roddy. Evaluation of CETP activity in vivo under non-steady-state conditions: influence of anacetrapib on HDL-TG flux.
Journal of lipid research.
2016 Mar; 57(3):398-409. doi:
10.1194/jlr.m063842. [PMID: 26658238] - C M Chavez-Eng, R W Lutz, H Li, D Goykhman, K P Bateman, E Woolf. Quantitation of anacetrapib, stable-isotope labeled-anacetrapib (microdose), and four metabolites in human plasma using liquid chromatography tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2016 Feb; 1011(?):204-14. doi:
10.1016/j.jchromb.2015.12.053. [PMID: 26773885] - Michael M Page, Amanda J Hooper, John R Burnett. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?.
Expert opinion on pharmacotherapy.
2016; 17(2):275-81. doi:
10.1517/14656566.2016.1129402. [PMID: 26642232] - Ben J Wu, Sudichhya Shrestha, Kwok L Ong, Douglas Johns, Louise L Dunn, Liming Hou, Philip J Barter, Kerry-Anne Rye. Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis.
International journal of cardiology.
2015 Nov; 199(?):204-12. doi:
10.1016/j.ijcard.2015.07.014. [PMID: 26204569] - Sam J L van der Tuin, Susan Kühnast, Jimmy F P Berbée, Lars Verschuren, Elsbet J Pieterman, Louis M Havekes, José W A van der Hoorn, Patrick C N Rensen, J Wouter Jukema, Hans M G Princen, Ko Willems van Dijk, Yanan Wang. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
Journal of lipid research.
2015 Nov; 56(11):2085-93. doi:
10.1194/jlr.m057794. [PMID: 26342106] - G Kees Hovingh, Kausik K Ray, S Matthijs Boekholdt. Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief?.
Circulation.
2015 Aug; 132(5):433-40. doi:
10.1161/circulationaha.115.014026. [PMID: 26240264] - Philip J Barter, Stephen J Nicholls, John J P Kastelein, Kerry-Anne Rye. Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case.
Circulation.
2015 Aug; 132(5):423-32. doi:
10.1161/circulationaha.114.014025. [PMID: 26240263] - John J P Kastelein, Joost Besseling, Sukrut Shah, Jean Bergeron, Gisle Langslet, G Kees Hovingh, Naab Al-Saady, Michiel Koeijvoets, John Hunter, Amy O Johnson-Levonas, Jennifer Fable, Aditi Sapre, Yale Mitchel. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.
Lancet (London, England).
2015 May; 385(9983):2153-61. doi:
10.1016/s0140-6736(14)62115-2. [PMID: 25743173] - Francisco J Rios, Karla B Neves, Aurelie Nguyen Dinh Cat, Sarah Even, Roberto Palacios, Augusto C Montezano, Rhian M Touyz. Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes.
The Journal of pharmacology and experimental therapeutics.
2015 Apr; 353(1):27-34. doi:
10.1124/jpet.114.221002. [PMID: 25617244] - Ben J Wu, Sudichhya Shrestha, Kwok L Ong, Douglas Johns, Liming Hou, Philip J Barter, Kerry-Anne Rye. Cholesteryl ester transfer protein inhibition enhances endothelial repair and improves endothelial function in the rabbit.
Arteriosclerosis, thrombosis, and vascular biology.
2015 Mar; 35(3):628-36. doi:
10.1161/atvbaha.114.304747. [PMID: 25633313] - Ronald M Krauss, Cathy Anne Pinto, Yang Liu, Amy O Johnson-Levonas, Hayes M Dansky. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
Journal of clinical lipidology.
2015 Jan; 9(1):93-102. doi:
10.1016/j.jacl.2014.09.013. [PMID: 25670366] - Eliot A Brinton, Uma Kher, Sukrut Shah, Christopher P Cannon, Michael Davidson, Antonio M Gotto, Tanya B Ashraf, Christine McCrary Sisk, Hayes Dansky, Yale Mitchel, Philip Barter. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
Journal of clinical lipidology.
2015 Jan; 9(1):65-71. doi:
10.1016/j.jacl.2014.10.005. [PMID: 25670362] - Eric J Niesor, Evelyne Chaput, Jean-Luc Mary, Andreas Staempfli, Andreas Topp, Andrea Stauffer, Haiyan Wang, Alexandre Durrwell. Effect of compounds affecting ABCA1 expression and CETP activity on the HDL pathway involved in intestinal absorption of lutein and zeaxanthin.
Lipids.
2014 Dec; 49(12):1233-43. doi:
10.1007/s11745-014-3958-8. [PMID: 25300953] - Antonio M Gotto, Uma Kher, Manash Shankar Chatterjee, Yang Liu, Xiujiang Susie Li, Sanskruti Vaidya, Christopher P Cannon, Eliot A Brinton, Jennifer E Moon, Sukrut Shah, Hayes M Dansky, Yale Mitchel, Philip Barter. Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study.
Journal of cardiovascular pharmacology and therapeutics.
2014 Nov; 19(6):543-9. doi:
10.1177/1074248414529621. [PMID: 24737712] - Hiroshi Mabuchi, Atsushi Nohara, Akihiro Inazu. Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.
Molecules and cells.
2014 Nov; 37(11):777-84. doi:
10.14348/molcells.2014.0265. [PMID: 25410905] - Tarja Äijänen, Artturi Koivuniemi, Matti Javanainen, Sami Rissanen, Tomasz Rog, Ilpo Vattulainen. How anacetrapib inhibits the activity of the cholesteryl ester transfer protein? Perspective through atomistic simulations.
PLoS computational biology.
2014 Nov; 10(11):e1003987. doi:
10.1371/journal.pcbi.1003987. [PMID: 25412509] - Brett Lauring, Xiujiang Susie Li, Yang Liu, Christy Corr, Nicole Lazarus, Josee Cote, Patrick Larson, Amy O Johnson Levonas, Kenneth C Lasseter, Richard A Preston, William B Smith, Eseng Lai, John A Wagner. Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib.
Journal of clinical pharmacology.
2014 Nov; 54(11):1247-55. doi:
10.1002/jcph.320. [PMID: 24782116] - Thomas P Roddy, David G McLaren, Ying Chen, Dan Xie, Keiana Dunn, Alison Kulick, Daphne Szeto, Gail Forrest, Kelly Albanese, Marcie Donnelly, Cesaire Gai, Andrew Gewain, Harmony Lederman, Kristian K Jensen, Xi Ai, Petr Vachal, Karen O Akinsanya, Michele A Cleary, Stephen F Previs, Hayes M Dansky, Douglas G Johns. Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques.
European journal of pharmacology.
2014 Oct; 740(?):410-6. doi:
10.1016/j.ejphar.2014.04.015. [PMID: 24769414] - François Briand, Quentin Thieblemont, Elodie Muzotte, Noémie Burr, Isabelle Urbain, Thierry Sulpice, Douglas G Johns. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
European journal of pharmacology.
2014 Oct; 740(?):135-43. doi:
10.1016/j.ejphar.2014.06.022. [PMID: 25008069] - Lacey B Robinson, William H Frishman. Anacetrapib: a potential new therapy for dyslipidemia.
Cardiology in review.
2014 Sep; 22(5):253-61. doi:
10.1097/crd.0000000000000023. [PMID: 24618931] - Bin Dong, Amar Bahadur Singh, Chin Fung, Kelvin Kan, Jingwen Liu. CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism.
Atherosclerosis.
2014 Aug; 235(2):449-62. doi:
10.1016/j.atherosclerosis.2014.05.931. [PMID: 24950000] - Nathan B Mantlo, Ana Escribano. Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk.
Journal of medicinal chemistry.
2014 Jan; 57(1):1-17. doi:
10.1021/jm400574e. [PMID: 23941686] - Ioanna Gouni-Berthold, Heiner K Berthold. Familial hypercholesterolemia: etiology, diagnosis and new treatment options.
Current pharmaceutical design.
2014; 20(40):6220-9. doi:
10.2174/1381612820666140620125213. [PMID: 24953396] - Antonio M Gotto, Christopher P Cannon, Xiujiang Susie Li, Sanskruti Vaidya, Uma Kher, Eliot A Brinton, Michael Davidson, Jennifer E Moon, Sukrut Shah, Hayes M Dansky, Yale Mitchel, Philip Barter. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.
The American journal of cardiology.
2014 Jan; 113(1):76-83. doi:
10.1016/j.amjcard.2013.08.041. [PMID: 24188894] - Daniel J Rader, Emil M deGoma. Future of cholesteryl ester transfer protein inhibitors.
Annual review of medicine.
2014; 65(?):385-403. doi:
10.1146/annurev-med-050311-163305. [PMID: 24422575] - Hyun Joon Shin, Peter A McCullough. Focus on lipids: high-density lipoprotein cholesterol and its associated lipoproteins in cardiac and renal disease.
Nephron. Clinical practice.
2014; 127(1-4):158-64. doi:
10.1159/000363552. [PMID: 25343842] - Michael B Boffa, Marlys L Koschinsky. Screening for and management of elevated Lp(a).
Current cardiology reports.
2013 Nov; 15(11):417. doi:
10.1007/s11886-013-0417-8. [PMID: 24057771] - Thomas A Bell, Mark J Graham, Richard G Lee, Adam E Mullick, Wuxia Fu, Dan Norris, Rosanne M Crooke. Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice.
Journal of lipid research.
2013 Oct; 54(10):2647-57. doi:
10.1194/jlr.m036509. [PMID: 23801661] - Sheng-Ping Wang, Erin Daniels, Ying Chen, Jose Castro-Perez, Haihong Zhou, Karen O Akinsanya, Stephen F Previs, Thomas P Roddy, Douglas G Johns. In vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorption.
Journal of lipid research.
2013 Oct; 54(10):2858-65. doi:
10.1194/jlr.m041541. [PMID: 23898048] - Amir Hooshang Mohammadpour, Fatemeh Akhlaghi. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Clinical pharmacokinetics.
2013 Aug; 52(8):615-26. doi:
10.1007/s40262-013-0071-8. [PMID: 23658137] - M Ezzahti, E J G Sijbrands, M T Mulder, J E Roeters van Lennep. Familial hypercholesterolaemia: new treatment options.
The Netherlands journal of medicine.
2013 Jun; 71(5):227-33. doi:
". [PMID: 23799308] - Seongah Han, Lauretta Levoci, Paul Fischer, Sheng-Ping Wang, Karen Gagen, Ying Chen, Dan Xie, Timothy Fisher, Anka G Ehrhardt, Andrea M Peier, Douglas G Johns. Inhibition of cholesteryl ester transfer protein by anacetrapib does not impair the anti-inflammatory properties of high density lipoprotein.
Biochimica et biophysica acta.
2013 Apr; 1831(4):825-33. doi:
10.1016/j.bbalip.2012.12.008. [PMID: 23269286] - Michael Davidson, Sherry Xueyu Liu, Philip Barter, Eliot A Brinton, Christopher P Cannon, Antonio M Gotto, Elizabeth T Leary, Sukrut Shah, Michael Stepanavage, Yale Mitchel, Hayes M Dansky. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.
Journal of lipid research.
2013 Feb; 54(2):467-72. doi:
10.1194/jlr.m032615. [PMID: 23172660] - Chuanwei Li, Wen Zhang, Faying Zhou, Caiyu Chen, Liang Zhou, Yafei Li, Ling Liu, Fang Pei, Hao Luo, Zhangxue Hu, Jing Cai, Chunyu Zeng. Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.
PloS one.
2013; 8(10):e77049. doi:
10.1371/journal.pone.0077049. [PMID: 24204732] - Mariarita Puntoni, Francesco Sbrana, Federico Bigazzi, Tiziana Sampietro. Tangier disease: epidemiology, pathophysiology, and management.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
2012 Oct; 12(5):303-11. doi:
10.2165/11634140-000000000-00000. [PMID: 22913675] - Bernd Hewing, Edward A Fisher. Rationale for cholesteryl ester transfer protein inhibition.
Current opinion in lipidology.
2012 Aug; 23(4):372-6. doi:
10.1097/mol.0b013e328353ef1d. [PMID: 22517614] - Ronald M Krauss, Kathleen Wojnooski, Joseph Orr, J Casey Geaney, Cathy Anne Pinto, Yang Liu, John A Wagner, Julie Mabalot Luk, Amy O Johnson-Levonas, Matt S Anderson, Hayes M Dansky. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.
Journal of lipid research.
2012 Mar; 53(3):540-547. doi:
10.1194/jlr.m018010. [PMID: 22180633] - Alyse S Goldberg, Robert A Hegele. Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.
Drug design, development and therapy.
2012; 6(?):251-9. doi:
10.2147/dddt.s34976. [PMID: 23055695] - Hisashi Shinkai. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Vascular health and risk management.
2012; 8(?):323-31. doi:
10.2147/vhrm.s25238. [PMID: 22661899] - D E Gutstein, R Krishna, D Johns, H K Surks, H M Dansky, S Shah, Y B Mitchel, J Arena, J A Wagner. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction.
Clinical pharmacology and therapeutics.
2012 Jan; 91(1):109-22. doi:
10.1038/clpt.2011.271. [PMID: 22130116] - Philip Barter, Kerry-Anne Rye. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?.
Trends in pharmacological sciences.
2011 Dec; 32(12):694-9. doi:
10.1016/j.tips.2011.07.004. [PMID: 22088767] - Jose Castro-Perez, François Briand, Karen Gagen, Sheng-Ping Wang, Ying Chen, David G McLaren, Vinit Shah, Rob J Vreeken, Thomas Hankemeier, Thierry Sulpice, Thomas P Roddy, Brian K Hubbard, Douglas G Johns. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters.
Journal of lipid research.
2011 Nov; 52(11):1965-73. doi:
10.1194/jlr.m016410. [PMID: 21841206] - Hayes M Dansky, Daniel Bloomfield, Patrice Gibbons, Sherry Liu, Christine McCrary Sisk, Diane Tribble, James M McKenney, Thomas W Littlejohn, Yale Mitchel. Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia.
American heart journal.
2011 Oct; 162(4):708-16. doi:
10.1016/j.ahj.2011.07.010. [PMID: 21982664] - Eric J Niesor. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Current opinion in lipidology.
2011 Aug; 22(4):288-95. doi:
10.1097/mol.0b013e3283475e00. [PMID: 21587074] - Rajesh Krishna, Arthur J Bergman, Michele Green, Marissa F Dockendorf, John A Wagner, Kevin Dykstra. Model-based development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor.
The AAPS journal.
2011 Jun; 13(2):179-90. doi:
10.1208/s12248-011-9254-0. [PMID: 21347617] - Marta A Miyares. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors.
The Annals of pharmacotherapy.
2011 Jan; 45(1):84-94. doi:
10.1345/aph.1p446. [PMID: 21205945] - Eric J Niesor, Christine Magg, Naoto Ogawa, Hiroshi Okamoto, Elisabeth von der Mark, Hugues Matile, Georg Schmid, Roger G Clerc, Evelyne Chaput, Denise Blum-Kaelin, Walter Huber, Ralf Thoma, Philippe Pflieger, Makoto Kakutani, Daisuke Takahashi, Gregor Dernick, Cyrille Maugeais. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
Journal of lipid research.
2010 Dec; 51(12):3443-54. doi:
10.1194/jlr.m008706. [PMID: 20861162] - Michael H Davidson. Update on CETP inhibition.
Journal of clinical lipidology.
2010 Sep; 4(5):394-8. doi:
10.1016/j.jacl.2010.08.003. [PMID: 21122682] - Mollie Ranalletta, Kathleen K Bierilo, Ying Chen, Denise Milot, Qing Chen, Elaine Tung, Caroline Houde, Nadine H Elowe, Margarita Garcia-Calvo, Gene Porter, Suzanne Eveland, Betsy Frantz-Wattley, Mike Kavana, George Addona, Peter Sinclair, Carl Sparrow, Edward A O'Neill, Ken S Koblan, Ayesha Sitlani, Brian Hubbard, Timothy S Fisher. Biochemical characterization of cholesteryl ester transfer protein inhibitors.
Journal of lipid research.
2010 Sep; 51(9):2739-52. doi:
10.1194/jlr.m007468. [PMID: 20458119] - Sanjeev Kumar, Eugene Y Tan, Georgy Hartmann, Zachary Biddle, Arthur J Bergman, James Dru, Jonathan Z Ho, Allen N Jones, Steve J Staskiewicz, Matthew P Braun, Bindhu Karanam, Dennis C Dean, Isaias Noel Gendrano, Mark W Graves, John A Wagner, Rajesh Krishna. Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans.
Drug metabolism and disposition: the biological fate of chemicals.
2010 Mar; 38(3):474-83. doi:
10.1124/dmd.109.028704. [PMID: 20016053] - Eugene Y Tan, Georgy Hartmann, Qing Chen, Antonio Pereira, Scott Bradley, George Doss, Andy Shiqiang Zhang, Jonathan Z Ho, Matthew P Braun, Dennis C Dean, Wei Tang, Sanjeev Kumar. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.
Drug metabolism and disposition: the biological fate of chemicals.
2010 Mar; 38(3):459-73. doi:
10.1124/dmd.109.028696. [PMID: 20016052] - J Pöss, M Böhm, U Laufs. [HDL and CETP in atherogenesis].
Deutsche medizinische Wochenschrift (1946).
2010 Feb; 135(5):188-92. doi:
10.1055/s-0030-1247862. [PMID: 20082258] - Ján Murín, Miroslav Pernický, Soňa Kiňová. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?].
Vnitrni lekarstvi.
Fall 201; 62(10):789-794. doi:
NULL. [PMID: 27900865] - Menno Vergeer, Erik S G Stroes. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.
The American journal of cardiology.
2009 Nov; 104(10 Suppl):32E-8E. doi:
10.1016/j.amjcard.2009.09.017. [PMID: 19895942] - Rajesh Krishna, Amit Garg, Deborah Panebianco, Josee Cote, Arthur J Bergman, Pascale Van Hoydonck, Tine Laethem, Kristien Van Dyck, Jingjing Chen, Cynthia Chavez-Eng, Laura Archer, Ryan Lutz, Deborah Hilliard, Karen Snyder, Bo Jin, Luc Van Bortel, Kenneth C Lasseter, Nidal Al-Huniti, Kevin Dykstra, Keith Gottesdiener, John A Wagner. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
British journal of clinical pharmacology.
2009 Oct; 68(4):535-45. doi:
10.1111/j.1365-2125.2009.03465.x. [PMID: 19843057] - Christopher P Cannon, Hayes M Dansky, Michael Davidson, Antonio M Gotto, Eliot A Brinton, A Lawrence Gould, Michael Stepanavage, Sherry Xueyu Liu, Sukrut Shah, Joseph Rubino, Patrice Gibbons, Anne Hermanowski-Vosatka, Bruce Binkowitz, Yale Mitchel, Philip Barter. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
American heart journal.
2009 Oct; 158(4):513-519.e3. doi:
10.1016/j.ahj.2009.07.028. [PMID: 19781408] - Daniel Bloomfield, Gary L Carlson, Aditi Sapre, Diane Tribble, James M McKenney, Thomas W Littlejohn, Christine McCrary Sisk, Yale Mitchel, Richard C Pasternak. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
American heart journal.
2009 Feb; 157(2):352-360.e2. doi:
10.1016/j.ahj.2008.09.022. [PMID: 19185645] - Rajesh Krishna, Arthur J Bergman, Bo Jin, Amit Garg, Brad Roadcap, Rita Chiou, James Dru, Josee Cote, Tine Laethem, Regina W Wang, Varsha Didolkar, Eva Vets, Keith Gottesdiener, John A Wagner. Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers.
Journal of clinical pharmacology.
2009 Jan; 49(1):80-7. doi:
10.1177/0091270008326718. [PMID: 19004846] - M J Forrest, D Bloomfield, R J Briscoe, P N Brown, A-M Cumiskey, J Ehrhart, J C Hershey, W J Keller, X Ma, H E McPherson, E Messina, L B Peterson, W Sharif-Rodriguez, P K S Siegl, P J Sinclair, C P Sparrow, A S Stevenson, S-Y Sun, C Tsai, H Vargas, M Walker, S H West, V White, R F Woltmann. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.
British journal of pharmacology.
2008 Aug; 154(7):1465-73. doi:
10.1038/bjp.2008.229. [PMID: 18536749] - T R Joy, R A Hegele. The failure of torcetrapib: what have we learned?.
British journal of pharmacology.
2008 Aug; 154(7):1379-81. doi:
10.1038/bjp.2008.248. [PMID: 18536741] - Rajesh Krishna, Matt S Anderson, Arthur J Bergman, Bo Jin, Marissa Fallon, Josee Cote, Kim Rosko, Cynthia Chavez-Eng, Ryan Lutz, Daniel M Bloomfield, Maria Gutierrez, James Doherty, Fredrick Bieberdorf, Jeffrey Chodakewitz, Keith M Gottesdiener, John A Wagner. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
Lancet (London, England).
2007 Dec; 370(9603):1907-14. doi:
10.1016/s0140-6736(07)61813-3. [PMID: 18068514]